Further exploration through individual cancer stages revealed that breast cancer patients exhibited heightened expressions of both CDC42 and ACTR2 across all AJCC (American Joint Committee on Cancer) stages, distinguishing them from normal patients (Figure S5). This evidence concerns the gene ACTR2 and breast carcinoma.